TCTR20201027001招募中未知
The newly diagnosed acute myeloid leukemia registry and ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sample collections for further investigating about molecular mutations
Siriraj Hospital Mahidol University0 个研究点目标入组 139 人开始时间: 2020年10月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 139
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •Thai patient newly diagnosed acute leukemia Myeloid Age group 18 years and over between 1 March 2018 and 31 December 2022 and participate sign ICF.
排除标准
- •The patients with hemoglobin level less than 5 g / dl. and the
- •patients with insufficient amount of radiosurgery needed for standard screening.
研究者
相似试验
终止
2 期
AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.Acute myeloid leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12619000248167Australian Leukaemia and Lymphoma Group (ALLG)5
招募中
2 期
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12619000280101Australian Leukaemia and Lymphoma Group (ALLG)75
尚未招募
2 期
AMLM22/D3 - The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12621000246886Australian Leukaemia and Lymphoma Group (ALLG)50
进行中（未招募）
不适用
Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic stem cellsAcute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplantEUCTR2005-000640-91-ESInstitut de Recerca Hospital Sta. Creu i St. Pau20
招募中
不适用
Acute Myeloid Leukemia Multimodal GenomicsCTRI/2019/04/018782Tata Trusts